BlinkLab is trading at A$0.63, up 6.78%, with no confirmed company-specific explanation for the October 21 rise.

  • The positive European ADHD study was reported in August, not today.
  • Healthcare-sector strength may provide supportive context, but available information does not establish it as the direct cause.
  • No reliable October 21 volume or activity-level detail was found, so trading activity cannot be characterized.